Figure 5 | Scientific Reports

Figure 5

From: YBX2 and cancer testis antigen 45 contribute to stemness, chemoresistance and a high degree of malignancy in human endometrial cancer

Figure 5

The expression of YBX2 and CT45 caused resistance to paclitaxel. (a) Chemosensitivity assay with IK-YBX2 C1 cells and IK mock cells. The number of IK-mock cells decreased over time after treatment with paclitaxel, while that of IK-YBX2 C1 cells was not changed. There were significant differences in the viable cell number at day 6 (*p < 0.05), and day 8 (**p < 0.01). (b) Chemosensitivity assay with IK-YBX2 C1 and C3-shCT45 cells and sh control cells was performed. The number of sh control cells increased over time. In contrast, the number of IK-YBX2-shCT45 cells decreased. There were significant differences in the viable cell number at day6 and day8 (*p < 0.05, **p < 0.01). (c) Chemosensitivity assay with IK-YBX2-shCT45-CT45 rescued cells and mock cells. Similar to IK-YBX2 cells, CT45-rescued cells displayed the stronger resistance to paclitaxel. There were significant differences in the viable cell number at day6 and day8 (*p < 0.05). Data represent the means ± SD from three independent experiments.

Back to article page